Ajay Major, MD, MBA @majorajay Twitter profile | Pikagi

Pikagi

Ajay Major, MD, MBA

@majorajay

6,558

Followers

1,690

Following

2,667

Media

14,305

Statuses

Lymphoma faculty @CUHematology . Patient-reported outcomes & quality of life researcher in #lymsm . Founder of & @inTrainingDoc . 🌈

Denver, CO

https://t.co/odzWg7FhAU

Joined November 2011

Don't wanna be here? Send us removal request.

Pinned Tweet

@majorajay

Ajay Major, MD, MBA

5 months

If you missed the #ASH23 Education Session by Dr. @mana1981 on CAR-T vs BiTEs in LBCL, our manuscript discusses pros and cons and our sequencing algorithm. If available, our preference is for CAR-T given its curative potential in real-world cohorts. #lymsm

Tweet media one

2

31

93

Last Seen Profiles

@in_locke

@Ghenedinho

@neural_machine

@Montreal

@paulaterradas9

@cherryhealey

@hunxho

@lowvanterz

@pgconfeu

@stunnabey

@oguzbikbik

@fea_kau

@carryyourcross

@carrfi06

@mimbale

@icecoldbanger

@reismemes

@PFF_IJF

@sheenasoomro

@omraut

@mrkvak

@finsta4nyaa

@alicia_wal64214

@RentJustice

@AbdulazizBulduk

@WorldVision

@wp_lanzarote

@kimskunoo

@GetTheKnaak

@ALlapashtica

@TheSafeAnnaAnon

@tksmith1104

@Helen_Barnard

@DimensionLatam

@LuccoMarcelo

@RealRamuncho

@majorajay

Ajay Major, MD, MBA

1 year

The most important trial at #ASH22 : NEUTRODIET, a randomized multicenter trial of 'neutropenic diet' vs normal diet after auto/alloSCT. No differences in infections, aGHVD or hospital days between arms. Less weight loss & better patient satisfaction in normal diet arm! #tcellrx

Tweet media one

Tweet media two

Tweet media three

10

132

392

@majorajay

Ajay Major, MD, MBA

2 years

All packed for Colorado! Elated to announce that I will be starting as an assistant professor at @CUAnschutz later this summer specializing in lymphoma and myeloma. See you soon, 5280 crew! cc @CUHemeOnc @CUHematology

48

7

343

@majorajay

Ajay Major, MD, MBA

8 years

SPOTTED: The coolest thing I have ever seen. #NYCBlizzard #WinterStormJonas #Blizzard2016 #jonasblizzard

Tweet media one

20

226

299

@majorajay

Ajay Major, MD, MBA

2 years

My first ASH oral presentation!!! 😭😭😭 #ASH22 cc @ASH_hematology

Tweet media one

30

2

269

@majorajay

Ajay Major, MD, MBA

2 years

It's official! A decade of medical training later, I am finally a hematologist and medical oncologist. Deeply honored to have trained with the faculty at @UChicago @UChicagoHemOnc . Next stop: assistant professor at @CUMedicalSchool @CUCancerCenter !

Tweet media one

24

9

251

@majorajay

Ajay Major, MD, MBA

5 years

Why #primarycare is one of the hardest jobs in medicine: a thread by a soon-to-be-graduating internal medicine resident. #meded #medtwitter It's 4pm on a Wednesday afternoon in resident clinic. Next is a 20-minute appointment for a 60-year-old woman for "sinus infection." (1/x)

13

37

175

@majorajay

Ajay Major, MD, MBA

3 years

Calling all trainees interested in #hematology : The 2021 @ASH_hematology Hematology Review Series is now open! It's a free online curriculum about a ton of hematology topics. Big thanks to the whole crew at the ASH Trainee Council who helped develop it!

2

40

144

@majorajay

Ajay Major, MD, MBA

4 years

I was feeling overwhelmed by all the laypress articles about #moralinjury and #burnout in frontline health care workers during #Covid_19 so I decided to do a deep dive into the literature on the mental health of workers during pandemics. Here's what I found. #thread 1/

8

50

141

@majorajay

Ajay Major, MD, MBA

2 years

Preparing for my first @ASH_hematology oral presentation at #ASH22 ! We have much more work to do for patients with relapsed lymphomas after CAR-T. A huge thanks to my mentor Dr. Kline @UChicagoHemOnc and all of our participating centers. #lymsm #tcellrx

Tweet media one

7

10

139

@majorajay

Ajay Major, MD, MBA

2 years

First day @CUAnschutz and I get a whole office?! #newjobnewdigs

Tweet media one

7

1

133

@majorajay

Ajay Major, MD, MBA

3 years

We are elated to announce the inaugural issue of Hematopoiesis, a new publication by the @ASH_hematology Trainee Council. A re-imagining of the previous ASH TraineE-News newsletter, take a look at our fresh, new publication by and for #hematology trainees. #thread 1/

Tweet media one

5

30

125

@majorajay

Ajay Major, MD, MBA

4 years

Hey #medtwitter , let's start a thread of drawings we make for patients. Just photos, no context. We must have some artists out there! Here's some of my chicken scratch I stumbled upon. #meded #medhum #artinmedicine #medhumchat #oncology

Tweet media one

25

20

124

@majorajay

Ajay Major, MD, MBA

2 years

I think it's pretty obvious that I'm going to @ASH_hematology #ASH21 . Looking forward to being in Atlanta in just a few hours! #ASHTrainee

Tweet media one

8

2

127

@majorajay

Ajay Major, MD, MBA

4 years

Academic medicine, you're drunk, go home. #medtwitter

Tweet media one

5

14

117

@majorajay

Ajay Major, MD, MBA

1 year

Cracked open my mother's clinical oncology book from 1978 (just 327 pages!). Check out the chapter on "The Malignant Lymphomas, Multiple Myeloma, and Macroglobulinemia" and all these regimens! Totally fascinating. #lymsm #mmsm

Tweet media one

Tweet media two

Tweet media three

Tweet media four

6

12

115

@majorajay

Ajay Major, MD, MBA

3 years

Elated to announce that I was voted Vice Chair of the @ASH_hematology Trainee Council! I will be succeeding the illustrious @Lachelle_Dawn as Chair in June 2021. I'm eager to help ASH become an even more inclusive organization for all hematology trainees. #hematologyproud

Tweet media one

12

3

115

@majorajay

Ajay Major, MD, MBA

3 years

My husband this morning imagining out loud what my life must be like on consults: "I cut this patient's arm off and now their hemoglobin is low. Could it be MDS?" 👀👀👀

10

2

108

@majorajay

Ajay Major, MD, MBA

1 year

Whew! Finally medical oncology & hematology boarded. Big shout out to Dr. Garg & @hemeoncquestion , brutally hard but amazing test prep. #onctwitter

Tweet media one

11

1

109

@majorajay

Ajay Major, MD, MBA

1 year

Our multicenter study of outcomes after checkpoint inhibitor therapy in the post-CAR-T setting is now @BloodAdvances ! Deeply appreciative to my mentor Dr. Kline @UCCancerCenter and all our collaborators. #lymsm #celltherapy cc @CULymphoma @CUHematology

Tweet media one

3

26

98

@majorajay

Ajay Major, MD, MBA

1 year

My first year of being a lymphoma attending is simultaneously terrifying, exhilarating, and deeply humbling. ✨This✨ is drinking from the fire hose. Please tell me I'm not the only one. 😂😂 #lymsm #hemetwitter

11

2

98

@majorajay

Ajay Major, MD, MBA

4 months

The @ASH_hematology #ASH23 Education Book is finally here! Check out our approach and algorithm to bispecific antibodies versus CAR-T for relapsed/refractory DLBCL. cc @mana1981 #lymsm #celltherapy

Tweet media one

Tweet media two

0

25

94

@majorajay

Ajay Major, MD, MBA

2 years

Calling all trainees interested in #hematology ! We are seeking writers for Hematopoiesis, our @ASH_hematology ASH Trainee Council publication by and for trainees: All levels of trainees can contribute. Submit your articles here:

Tweet media one

3

39

89

@majorajay

Ajay Major, MD, MBA

9 months

Our multicenter study of checkpoint inhibitor outcomes in the post-CAR-T setting is now published in full @BloodAdvances . Response rates & survival are poor with these agents and novel approaches (such as bispecifics) are needed. #lymsm #celltherapy

Tweet media one

3

20

87

@majorajay

Ajay Major, MD, MBA

2 years

As a lymphoma doc, I am very interested in how active surveillance ("watch and worry") affects #qualityoflife in patients with indolent lymphomas. Follow along in this #thread for our recent paper looking at longitudinal QOL & PROs in this specific population. #lymsm 1/

Tweet media one

6

15

86

@majorajay

Ajay Major, MD, MBA

6 months

Nivo-AVD >> BV-AVD age 60+ S1826 @DrAEvens #ASH23 : - 97 pts, 47% IPS 4+ - 1-yr PFS 93% N-AVD (vs 64% BV-AVD); 👀those curves! - less sepsis/infx in N-AVD; more neuropathy in BV (49% Gr 2+!) - 14% NRM with BV-AVD! (v 4% N-AVD) New SOC for older cHL! #lymsm

Tweet media one

3

23

83

@majorajay

Ajay Major, MD, MBA

2 years

My first time at the @ASH_hematology HQ in D.C.! I'm representing the ASH Trainee Council at today's Committee on Training meeting to plan for ASH-a-Palooza at #ASH22 . Get excited for NOLA! #ASHTrainee

Tweet media one

5

3

83

@majorajay

Ajay Major, MD, MBA

4 years

Late night publication of this phenomenal piece on @inHouseMag by an internal medicine resident and PhD anthropologist who lived in Wuhan on radical changes needed in our infection control practices. #covid19 #covid4MDs #PPE #CoronavirusUSA

Tweet card media

Routine Infection Prevention Will Not Contain COVID-19

As an internal medicine resident working at Mount Sinai Hospital in Manhattan, COVID-19 has taken over our workroom conversations as the number of new cases enters exponential growth. As an anthrop...

in-housestaff.org

4

55

80

@majorajay

Ajay Major, MD, MBA

1 year

IT'S REAL. THE FRIDAY ACUTE LEUK IS REAL. (But not prognostic!) HT @PallawiTorkaMD cc @HemOncFellows #leusm #ASH22

Tweet media one

5

22

81

@majorajay

Ajay Major, MD, MBA

2 years

Excited to announce that I'll be co-hosting the inaugural LGBTQIA+ Community Networking Brunch at #ASH22 ! 🩸🏳️‍🌈🎉 Mark your calendars: Sunday, December 11, 2022, 11:15-12:15 PM. Huge thanks to the @ASH_hematology DEI Committee for supporting this new event! #ASHTrainee

6

7

80

@majorajay

Ajay Major, MD, MBA

2 years

Last myeloma clinic of fellowship @UCCancerCenter ! A silly last-day surprise from an amazing team. ❤️❤️ #mmsm

Tweet media one

2

4

80

@majorajay

Ajay Major, MD, MBA

1 year

These predatory journals are just vicious nowadays. #academictwitter

Tweet media one

12

2

79

@majorajay

Ajay Major, MD, MBA

2 years

Elated to be joining the @CUMedicalSchool @CCTSI Clinical Faculty Scholars Program as the next stepping stone in becoming an independent investigator. Many thanks to Dr. @AnneLibbyPhD and @CUHematology for the opportunity!

Tweet media one

11

4

78

@majorajay

Ajay Major, MD, MBA

6 months

Pembro+AVD in 1L cHL #ASH23 : - 50 pts, mF/U 2.3 yrs - 2-yr PFS 97%, OS 100% (!!!), including adv-stage pts (look at those curves!) - iPET2 not prognostic (and some EOT PET+ pts still without PD) Will have to rethink PET with CPI (role for ctDNA!) #lymsm

Tweet media one

2

15

75

@majorajay

Ajay Major, MD, MBA

2 years

Elated to announce the @JCOOP_ASCO publication of our mixed-methods study of pandemic's impact on heme/onc trainees, with my co-author @UDurani and spearheaded by @Lachelle_Dawn . Full tweetorial thread to follow when partner piece is published. #MedTwitter

Tweet media one

4

22

75

@majorajay

Ajay Major, MD, MBA

5 months

Happy holidays to all you folks working in hospitals today! 🎄🎁 #xmasbmtcrew #lymsm

Tweet media one

3

5

74

@majorajay

Ajay Major, MD, MBA

2 years

Happy @ash_hematology week! After reviewing all the patient-reported outcomes ( #PROs ) abstracts at #ASH21 this year, I'll be summarizing my top 20 #MajorPROs abstracts in this #thread . Follow along for a slew of thought-provoking (and provocative!) studies.

Tweet media one

1

17

73

@majorajay

Ajay Major, MD, MBA

3 years

After a year of hard work with the @ASH_hematology Trainee Council, we are elated to announce our new #podcast , Hematopoiesis! Check out the teaser episode with @Lachelle_Dawn and I: And stay tuned for the new Hematopoiesis newsletter in a few weeks!

Tweet card media

Hematopoiesis: An ASH Trainee Council Production

Listen to Hematopoiesis: An ASH Trainee Council Production on Spotify. The American Society of Hematology Trainee Council is proud to announce the creation of a new podcast to accompany our new...

open.spotify.com

2

20

74

@majorajay

Ajay Major, MD, MBA

1 year

Kite just announced a significant overall survival benefit (!!!) of axi-cel from the ZUMA-7 randomized trial as compared to ASCT in second-line high-risk DLBCL. Hoping to see the data at #ASCO23 . #lymsm #celltherapy HT @Eddie_Cliff

Tweet media one

1

14

73

@majorajay

Ajay Major, MD, MBA

9 years

BREAKING: South Side of #Chicago will be getting trauma center. The power of grassroots activism. #TraumaCenterNow http://t.co/OXdfDP8gue

Tweet card media

South Side to get adult trauma center after years of protest

After years of protests by community activists demanding access to urgent medical care, University of Chicago Medicine and Sinai Health System on Thursday announced a $40 million joint project to o…

www.chicagotribune.com

0

103

68

@majorajay

Ajay Major, MD, MBA

1 year

Deeply honored that our @ASH_hematology #ASH22 abstract on outcomes of checkpoint inhibitors after post-CAR-T relapse will be featured in Highlights of ASH. Many thanks to all our collaborators. Manuscript is on the way! ✍🏽✍🏽 #lymsm #celltherapy

Tweet media one

2

3

72

@majorajay

Ajay Major, MD, MBA

1 year

Get ready for some serious tweeting at #ASH22 ! Check out the @ASH_hematology social media guide and be sure to follow all of us for live updates during the conference. #ASHKudos

Tweet media one

Tweet media two

3

15

70

@majorajay

Ajay Major, MD, MBA

3 years

Check out our latest article on Hematopoiesis, the new @ASH_hematology ASH Trainee Council publication by and for trainees: @CEKanakisMD & @KMirza contribute a Morning Report review on the #hemepath basics of the bone marrow biopsy, with virtual slides!

Tweet media one

Tweet media two

3

19

68

@majorajay

Ajay Major, MD, MBA

1 year

If you need more incentive to tweet after Dr. @acweyand 's social media talk yesterday, I just got a bunch of free @ASH_hematology swag for being a top #ASH22 tweeter! #ASHTrainee

Tweet media one

3

5

66

@majorajay

Ajay Major, MD, MBA

2 years

First clinic! Thank you to @CUHematology for such a warm welcome. 🥹🥹🥹 #lymsm

Tweet media one

2

6

68

@majorajay

Ajay Major, MD, MBA

2 years

As a lymphoma doc, I am particularly interested in how active surveillance ("watch and wait") affects QOL in patients with indolent lymphomas/CLL. Check out our just-published study in a real-world cohort! Thread coming tomorrow. #lymsm #qualityoflife

Tweet media one

2

12

67

@majorajay

Ajay Major, MD, MBA

4 years

Welp, here's me and my husband being super unprofessional marching in the Boston #GayPride parade in 2014, a whole year before we got equal rights under the law. Professionalism has been weaponized in medicine. #medtwitter #medbikini #unprofessionalmedtwitter #unprofessional

Tweet media one

3

4

66

@majorajay

Ajay Major, MD, MBA

3 years

Elated to see our review of R-CHOP vs DA-R-EPOCH on the front cover of @clinadvances ! (tl;dr: I read all of the R-CHOP papers so that you don't have to -- Table 2 breaks it all down.) #lymsm

Tweet media one

4

19

65

@majorajay

Ajay Major, MD, MBA

2 years

You know #ASH21 is back in full swing when you have drug ads waiting on your hotel door, a sick view from the hotel, and even an @ASH_hematology -branded ferris wheel. Get pumped for a great weekend!

Tweet media one

Tweet media two

2

2

64

@majorajay

Ajay Major, MD, MBA

5 months

Huge #ASH23 meta-analysis by @KRejeski et al. demonstrating 1) 58% of CAR-T studies don't report NRM, and 2) 48% of CAR-T-associated NRM is caused by infections. Other interesting point: 6% of NRM caused by second cancers? #lymsm #mmsm #celltherapy

Tweet media one

0

12

64

@majorajay

Ajay Major, MD, MBA

2 years

In my (very) short tenure as a lymphoma doctor, I have tremendous respect for the first cycle effect in older folks receiving R-CHOP for DLBCL. Huge fan of prephase treatment and steroids to help mitigate, as well as anti-infective prophylaxis and a mid-C1 symptom check. #lymsm

5

5

64

@majorajay

Ajay Major, MD, MBA

1 year

New standard of care for CLL/SLL: zanubrutinib with better PFS than ibrutinib (especially in patients with TP53 mutations), and also less toxic, with no cardiac deaths with zanu versus 2% in ibrutinib arm. #lymsm #leusm #ASH22

Tweet media one

0

16

63

@majorajay

Ajay Major, MD, MBA

11 months

Eagerly awaiting Dr. @CwynKate 's #17ICML talk this morning @icmlugano on the management of primary & secondary CNS lymphomas. Wonderful consensus paper is now online, and the figures (included the CNS prophylaxis figure below) are phenomenal! #lymsm

Tweet media one

1

23

62

@majorajay

Ajay Major, MD, MBA

8 years

"Culture of appearing competent" is part of the hidden curriculum in #meded and is a barrier to creating a culture of wellbeing. #aamc16

2

48

56

@majorajay

Ajay Major, MD, MBA

2 years

"This study suggests credit score may have a utility as a companion to traditional metrics used in identifying candidates for surgery residencies and fellowships..." 😱😱😱 Who on EARTH thought this study was a good idea?! #meded

Tweet card media

Predictive Value of Credit Score on Surgery Resident and Fellow Academic and Professional Perform...

IntroductionSurgical specialties consistently remain among the most competitive residency and fellowship programs with some of the highest rates of unmatched applicants. Attrition in surgical...

www.ncbi.nlm.nih.gov

16

10

61

@majorajay

Ajay Major, MD, MBA

1 year

Here we go! Announcing this year's top 20 patient-reported outcomes abstracts at #ASH22 . Follow along in this thread for the latest thought-provoking (and provocative!) #qualityoflife studies in hematology. 🧵 #MajorPROs #MajorPROsASH #ASH2022 cc @ASH_hematology

Tweet media one

2

16

58

@majorajay

Ajay Major, MD, MBA

3 years

Refreshing (and overdue) perspective in @NEJM . I really would love to donate blood during this unprecedented shortage. 🏳️‍🌈🏳️‍🌈🏳️‍🌈

Tweet card media

Blood Donation by Gay and Bisexual Men — The Need for a Policy Update | NEJM

The United Kingdom recently amended its eligibility criteria for blood donation to screen out potential donors on the basis of individualized risk assessment rather than blanket criteria excluding ...

1

8

57

@majorajay

Ajay Major, MD, MBA

8 years

I MATCHED! I'll be at @MedicineCU next year for internal medicine! #Match2016 #iMatched #MatchDay

Tweet media one

13

2

59

@majorajay

Ajay Major, MD, MBA

8 months

Dr. @lymphomatic 's current algorithm for CNS prophylaxis & frontline LBCL treatment at #SOHO23 . #lymsm

Tweet media one

3

23

58

@majorajay

Ajay Major, MD, MBA

2 years

Great summary slide on all RCTs for primary CNS lymphoma induction regimens from #IUCLS2022 . #lymsm

Tweet media one

0

11

59

@majorajay

Ajay Major, MD, MBA

2 years

My last official @ASH_hematology ASH Trainee Council meeting. Handing over the reins to the illustrious Dr. @beckyzon , who is already driving multiple new initiatives for the hematology trainee community. Deeply honored to have worked with this phenomenal crew. 🥰🥰 #ASHTrainee

Tweet media one

3

4

58

@majorajay

Ajay Major, MD, MBA

2 years

Please stop saying patients failed therapies. I've heard it time and time again at #ASH21 , including at plenary sessions. We can do better than this.

4

8

57

@majorajay

Ajay Major, MD, MBA

2 years

D-1 until @ASH_hematology #ASH21 and making sure to pack my lucky blood smear socks! See you all very soon. #ASHTrainee

Tweet media one

6

2

56

@majorajay

Ajay Major, MD, MBA

4 years

Phenomenal piece by @readwriteradio in today's @NewYorker about the backlash against frontline residents who petitioned for #hazardpay in NYC. Featuring quotes by @colleenmfarrell and myself! #covid19 #medtwitter

Tweet card media

What Happened When Medical Residents Asked for Hazard Pay

At the peak of the pandemic in New York, residents at a multibillion-dollar hospital system asked for better working conditions. The ensuing debate highlighted the profession’s persistent inequities.

www.newyorker.com

1

27

54

@majorajay

Ajay Major, MD, MBA

1 year

The FDA approves pola-R-CHP for untreated DLBCL and HGBL with IPI score of 2 or greater! #lymsm

Tweet card media

FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL

The FDA has approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone for use in adult patients who have previously untreated diffuse large...

www.onclive.com

2

15

52

@majorajay

Ajay Major, MD, MBA

2 years

Just swabbed for @BeTheMatch ! A little new year's resolution checked off. #BeTheMatch #bmtsm

Tweet media one

2

2

52

@majorajay

Ajay Major, MD, MBA

6 months

Epcoritamab in R/R FL #ASH23 : - 128 pts, all 2+ prior LOT, 42% POD24 - ORR 82% (CR 63%), med time to response 1.4 mos - mPFS 15.4 mos (74% of CRs sustained @ 18 mos) - MRD negativity➡️PFS - 10% fatal TEAEs??? Indefinite therapy, tho. #lymsm

Tweet media one

6

20

53

@majorajay

Ajay Major, MD, MBA

1 year

Beautiful sunny (and chilly!) winter wonderland @CUAnschutz @CUMedicalSchool while on BMT service today. Happy holidays, y'all! #denver

Tweet media one

2

0

54

@majorajay

Ajay Major, MD, MBA

2 years

Applications for the @ASH_hematology ASH Trainee Council are now open! It's a phenomenal opportunity to shape the future of hematology training. Check out the link below for instructions on how to apply; applications are due April 29. #ASHTrainee

Tweet media one

0

26

53

@majorajay

Ajay Major, MD, MBA

5 years

Your first patient of the morning is being roomed. At least it's not a 'sinus infection.' You hope, anyway. (20/20) fin.

4

0

53

@majorajay

Ajay Major, MD, MBA

1 year

Deeply grateful to all our co-investigators and my @UCCancerCenter fellowship mentor Dr. Kline for the opportunity to present our study of poor outcomes with checkpoint inhibitors in the post-CAR-T relapse setting at @ASH_hematology #ASH22 today. #lymsm

Tweet media one

Tweet media two

Tweet media three

1

3

53

@majorajay

Ajay Major, MD, MBA

8 months

Dr. @NitinJainMD 's unanswered questions in CLL at #SOHO23 . #leusm #lymsm

Tweet media one

3

10

52

@majorajay

Ajay Major, MD, MBA

4 years

Does anyone else put '***' when writing manuscripts or emails thinking you can later F2 through everything? @EPICEMRparody #epic

4

2

52

@majorajay

Ajay Major, MD, MBA

2 years

Venetoclax in t(11;14) myeloma is one helluva drug. Some legit tumor lysis, too! #mmsm #hemetwitter

Tweet media one

6

5

52

@majorajay

Ajay Major, MD, MBA

2 years

It's a sorry state of affairs in peer review right now. Uncompensated work for overburdened folks. #AcademicTwitter #MedTwitter

Tweet media one

5

6

52

@majorajay

Ajay Major, MD, MBA

2 years

Covering our inpatient BMT service this weekend so that our wonderful @CUHematology APPs can enjoy their annual retreat! Huge thanks to all our NPs and PAs for their expert management of our patients. #weekendvibes

Tweet media one

1

4

52

@majorajay

Ajay Major, MD, MBA

1 year

The one and only Dr. @acweyand (who I finally met!) giving a main stage ASH-a-Palooza talk about using social media as a hematologist. #ASH22 #ASHTrainee

Tweet media one

3

6

52

@majorajay

Ajay Major, MD, MBA

11 years

"The patient refused autopsy" and more hilarious actual chart entries. cc: @LifeofMedstudnt @OHMedSchool #meded http://t.co/0AyZlh16I9

Tweet media one

4

59

48

@majorajay

Ajay Major, MD, MBA

3 years

It's such an incredible honor to be chief fellow next year. Thank you to the faculty (and all my co-fellows!) at @UCCancerCenter !

@UCHemOncFellows

University of Chicago Hem/Onc Fellows

@UCHemOncFellows

3 years

We are thrilled to announce that current 2nd-year fellow @majorajay will be serving as chief fellow for the 2021-2022 academic year! Dr. Major has been an incredible advocate for trainees at U of C & through the @ASH_hematology Trainee Council, we are a lucky fellowship program!

Tweet media one

3

2

35

3

0

51

@majorajay

Ajay Major, MD, MBA

3 months

AFM13-complexed NK product for R/R CD30+ cHL at #DenverASHReview : 42 pts, no CRS/ICANS or GVH, ORR 97% (78% CR!), most of which had previous BV. DOR still not great due to NK persistence issues, but very promising early-phase data. #lymsm cc @BradHaverkos

Tweet media one

Tweet media two

Tweet media three

Tweet media four

3

13

51

@majorajay

Ajay Major, MD, MBA

2 years

Great summary slide of response and survival rates for agents in the r/r DLBCL. #IUCLS2022 #lymsm

Tweet media one

1

15

51

@majorajay

Ajay Major, MD, MBA

2 years

NBD, just me looking slightly bewildered on @ASH_hematology #ASH21 ASH News TV. 😂😂😂

Tweet media one

3

1

51

@majorajay

Ajay Major, MD, MBA

1 year

Best morning snack to begin the last day of @ASH_hematology #ASH22 . It was great to network with all you brilliant hematologists! Please do stay in touch (and will hopefully see some of you at #ASCO23 .) #lymsm #mmsm

Tweet media one

2

0

50

@majorajay

Ajay Major, MD, MBA

5 months

Rituximab for EBV+ after solid organ tplant to prevent PTLD #ASH23 : - 2168 pts (!!!), median time SOT➡️EBV+ 688d - 1.6% of pts who received R got PTLD - 10% of pts didn't get R got PTLD - OR 0.15 for PTLD in pts who got post-SOT R Huge cohort! #lymsm

Tweet media one

2

12

50

@majorajay

Ajay Major, MD, MBA

2 years

Excited to see all you #ASH21 trainees at @ASH_hematology ASH-a-Palooza tomorrow! Quick reminder to register and pick up your badges at the convention center before heading over. Your vaccine status has to be verified beforehand. #ASHTrainee

Tweet media one

1

6

48

@majorajay

Ajay Major, MD, MBA

1 year

Phenomenal study @ouholter of at-home transfusion support during hospice. Transfusions = improved symptom burden, no hospice revocations, only 3 units given, and all pts died at home. #ASH22 #hpm #geripal

Tweet media one

2

11

48

@majorajay

Ajay Major, MD, MBA

5 years

Holy cow, it's happening! #fellowship #meded #medtwitter

Tweet media one

1

1

47

@majorajay

Ajay Major, MD, MBA

6 months

BsAb➡️CAR outcomes @gloria_iacoboni #ASH23 : - 47 pts got BsAb before CAR apheresis - median BsAb 98 days; median washout 43 days - post-CAR: ORR 83% (no diff based on prev BsAb response), mPFS 6.6 mos, mOS NR - no diff in PFS/OS re: washout timing #lymsm

Tweet media one

0

13

47

@majorajay

Ajay Major, MD, MBA

2 years

After our two recent publications @JCOOP_ASCO on the experience of hematology/oncology trainees and program directors during the #COVID19 pandemic, let's dive into our findings and other literature re: how #meded can provide better support. Follow the #thread ! ⬇️⬇️⬇️ #fellowship

Tweet media one

Tweet media two

1

24

48

@majorajay

Ajay Major, MD, MBA

2 years

DLBCL is multiple diseases! Saving these slides from #DAVAWhistler2022 on the evolving genetic landscape of DLBCL and rational targeted agents. Last slide is the basis for TEDDI-R in CNS lymphoma. #lymsm cc @SoniSmithMD

Tweet media one

Tweet media two

Tweet media three

2

7

47

@majorajay

Ajay Major, MD, MBA

6 months

PD1 before ASCT in R/R cHL #ASH23 : - 981 pts (!!), 20% PD1 / 32% BV before ASCT - 2-yr PFS 93% with PD1 (vs 74% with BV & 72% with chemo); no diff in OS - similar PFS & OS in PD1+BV vs PD1+chemo Great confirmatory data. Love pembro-GVD! #lymsm

Tweet media one

2

16

46

@majorajay

Ajay Major, MD, MBA

3 years

There is a hidden curriculum within academic heme/onc which devalues clinician-educators and #meded research, despite pressing needs for both. Dedicated training pathways and grant support are vital components of this paradigm shift, particularly in the absence of strong mentors.

@ASCO

ASCO

3 years

To meet future practice demands, oncologists must encourage individuals to pursue careers as educators & support existing clinician-educators. @MeredithGiulia1 calls for more research & advocacy in this area in a recent #ASCODailyNews editorial 👩‍🏫

Tweet media one

0

24

63

2

8

47

@majorajay

Ajay Major, MD, MBA

1 year

Okay, but getting a shout-out citation during the @FDAOncology ODAC meeting on pola-R-CHP was not on my 2023 bingo card. (Huge thanks to Dr. @SoniSmithMD for her mentorship on our paper!) #lymsm

Tweet media one

1

6

47

@majorajay

Ajay Major, MD, MBA

1 year

Hearing patient-reported outcomes being collected in almost every one of the #ASH22 late-breaking abstracts is phenomenal. How far we've come as a hematology community. Looking forward to seeing the results in print! @ASH_hematology

2

3

44

@majorajay

Ajay Major, MD, MBA

1 year

@ChrisCarrollMD Never. Literally never. Where are they losing blood?! 😨😨😨

1

0

46

@majorajay

Ajay Major, MD, MBA

11 months

10-yr CLL12 follow-up results #17ICML - 363 pts with asympt CLL at increased risk randomized to placebo vs ibrutinib - ibr arm with improved EFS/PFS/TTNT - no diff in OS! - much more cardiotox in ibr arm Impressive study in the BTK era that supports watch & wait. #lymsm

Tweet media one

Tweet media two

1

11

45

@majorajay

Ajay Major, MD, MBA

1 year

Happy #ASH22 week! After reviewing all the patient-reported outcomes abstracts @ash_hematology this year, I'll be highlighting my top 20 #MajorPROs abstracts starting tomorrow, with new additions I find down in #NOLA . Stay tuned! #MajorPROsASH

Tweet media one

1

6

46

@majorajay

Ajay Major, MD, MBA

2 years

Excited for this #ASH21 plenary session! ctDNA for MRD monitoring in CNS lymphoma. Utility in both diagnosis of CNS involvement as well as detection of relapse. #lymsm #thread 🔽🔽🔽

Tweet media one

1

14

46

@majorajay

Ajay Major, MD, MBA

5 months

Interested in seeing how quality of life changes in patients after receiving CAR-T? Check out this quick thread reviewing our #ASH23 abstract about longitudinal PROs incorporated into a prospective CAR-T biobank registry. #lymsm #mmsm #celltherapy 🧵/1

Tweet media one

1

10

47

@majorajay

Ajay Major, MD, MBA

1 year

This is peak hematology nerddom. Well done, @ASH_hematology . #ASH22

@ReshmaRamlal2

Reshma Ramlal

1 year

Red has gotten some friends #ASH22

Tweet media one

2

17

162

1

5

45